Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

543 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.
Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RA. Stock W, et al. Among authors: bloomfield cd. Cancer. 2013 Jan 1;119(1):90-8. doi: 10.1002/cncr.27617. Epub 2012 Jun 28. Cancer. 2013. PMID: 22744771 Free PMC article. Clinical Trial.
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, Stewart CC, Hurd DD, Kolitz JE, Velez-Garcia E, Stone RM, Bloomfield CD, Schiffer CA, Larson RA. Szatrowski TP, et al. Among authors: bloomfield cd. Cancer. 2003 Mar 15;97(6):1471-80. doi: 10.1002/cncr.11219. Cancer. 2003. PMID: 12627512 Free article. Clinical Trial.
Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251.
Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA. Rizzieri DA, et al. Among authors: bloomfield cd. Cancer. 2004 Apr 1;100(7):1438-48. doi: 10.1002/cncr.20143. Cancer. 2004. PMID: 15042678 Free article. Clinical Trial.
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, Baer MR, Davey FR, Bloomfield CD, Larson RA, Schiffer CA. Moore JO, et al. Among authors: bloomfield cd. Blood. 2005 May 1;105(9):3420-7. doi: 10.1182/blood-2004-08-2977. Epub 2004 Nov 30. Blood. 2005. PMID: 15572587 Free PMC article. Clinical Trial.
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J; Children's Cancer Group; Cancer and Leukemia Group B studies. Stock W, et al. Among authors: bloomfield cd. Blood. 2008 Sep 1;112(5):1646-54. doi: 10.1182/blood-2008-01-130237. Epub 2008 May 23. Blood. 2008. PMID: 18502832 Free PMC article. Clinical Trial.
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA; Cancer and Leukemia Group B. Stone RM, et al. Among authors: bloomfield cd. Cancer Chemother Pharmacol. 2009 Apr;63(5):859-64. doi: 10.1007/s00280-008-0805-8. Epub 2008 Aug 1. Cancer Chemother Pharmacol. 2009. PMID: 18670778 Clinical Trial.
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C 3rd, Stone RM, Bloomfield CD, Larson RA; Cancer and Leukemia Group. Grinblatt DL, et al. Among authors: bloomfield cd. Cancer. 2009 Jan 1;115(1):84-93. doi: 10.1002/cncr.23995. Cancer. 2009. PMID: 19025972 Free PMC article. Clinical Trial.
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA; Alliance for Clinical Trials in Oncology. Kolitz JE, et al. Among authors: bloomfield cd. Cancer. 2014 Apr 1;120(7):1010-7. doi: 10.1002/cncr.28516. Epub 2013 Dec 31. Cancer. 2014. PMID: 24382782 Free PMC article. Clinical Trial.
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Baer MR, et al. Among authors: bloomfield cd. Blood. 2002 Aug 15;100(4):1224-32. Blood. 2002. PMID: 12149202 Free article. Clinical Trial.
543 results